Total trials
1,053
Active
234
Phase 3
42
Total enrollment
1,193,123
Pipeline matrix
Showing 40 of 47 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexamethasone | — | — | — | — | — | 3 | |
| Surfactant | — | — | — | — | — | 2 | |
| SYSTANE® PRO | — | — | — | — | — | 1 | |
| MIEBO™ | — | — | — | — | — | 1 | |
| Netarsudil Ophthalmic Solution | — | — | — | — | — | 1 | |
| Ondansetron 8mg | — | — | — | — | — | 1 | |
| Trimethoprim Sulfamethoxazole | — | — | — | — | — | 1 | |
| sufentanil | — | — | — | — | — | 1 | |
| methadone | — | — | — | — | — | 1 | |
| PEG 3350 | — | — | — | — | — | 1 | |
| PEG-3350 with electrolytes | — | — | — | — | — | 1 | |
| Glycerin | — | — | — | — | — | 1 | |
| Heliox inspirate | — | — | — | — | — | 1 | |
| Cervical ripening with a double balloon catheter plus misoprostol | — | — | — | — | — | 1 | |
| Usual-care control group | — | — | — | — | — | 1 | |
| Inrathecal Morphine | — | — | — | — | — | 1 | |
| Intravenous Methadone | — | — | — | — | — | 1 | |
| CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID | — | — | — | — | — | 1 | |
| Slow Release DHEA | — | — | — | — | — | 2 | |
| SAMe 400 mg | — | — | — | — | — | 1 | |
| Guanfacine Extended Release | — | — | — | — | — | 1 | |
| Psilocybin | — | — | — | — | — | 1 | |
| Tapinarof | — | — | — | — | — | 1 | |
| Extended Release Niacin | — | — | — | — | — | 1 | |
| 5-Hydroxytryptophan | — | — | — | — | — | 1 | |
| Alkaline glycine | — | — | — | — | — | 1 | |
| Optate | — | — | — | — | — | 1 | |
| Zanzalintinib | — | — | — | — | — | 1 | |
| Etoposide | — | — | — | — | — | 1 | |
| Lacosamide | — | — | — | — | 2 | ||
| Caffeine citrate | — | — | — | — | — | 1 | |
| Intravenous Alcohol | — | — | — | — | — | 1 | |
| Carbon Dioxide | — | — | — | — | — | 1 | |
| [18F]-AraG radiotracer | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Methadone and Tizanidine | — | — | — | — | — | 1 | |
| Efavirenz, Methadone and Tizanidine | — | — | — | — | — | 1 | |
| ICI Therapy | — | — | — | — | — | 1 | |
| Menthol Gel | — | — | — | — | — | 1 | |
| Gardisil-9 | — | — | — | — | — | 2 |
7 more active programs hidden
Next readouts
- 2026-03
- 2026-05-01
- 2026-05-31
- 2026-06-30
- 2026-06-30
- 2026-07
- 2026-07
- 2026-08-15
- 2026-08-31
- 2026-09-30
Top conditions
- Depression32
- Anxiety28
- Breast Cancer18
- Alzheimer Disease17
- Asthma16
- Dementia14
- Gastroparesis14
- Healthy13
Frequently asked questions about Indiana University
- How many clinical trials does Indiana University have on ClinicalTrials.gov?
- Indiana University is listed as the lead sponsor on 1,053 clinical trials in ClinicalTrials.gov, 234 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Indiana University's trials are in Phase 3?
- 42 of Indiana University's trials are in Phase 3, spread across 47 active drug programs.
- What therapeutic areas does Indiana University focus on?
- Indiana University's most-studied conditions on ClinicalTrials.gov are Depression, Anxiety, Breast Cancer, Alzheimer Disease, Asthma.
- When are Indiana University's next clinical trial readouts?
- Indiana University has 10 upcoming primary-completion readouts tracked here; the soonest is “Menthol Stimulation of Brown Adipose Tissue in Humans: Aim 1”, expected around 2026-03.